AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Takeda Pharmaceutical Li... (TAK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.90

0.36 (2.66%)

At close: Feb 18, 2025, 3:59 PM

13.90

0.00%

After-hours: Feb 18, 2025, 07:00 PM EST

undefined% (undefined)

Bid	13.81
Market Cap	44.07B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.42
PE Ratio (ttm)	33.1
Forward PE	n/a
Analyst	Buy

Ask	14
Volume	1,420,020
Avg. Volume (20D)	1,830,686
Open	13.81
Previous Close	13.54
Day's Range	13.76 - 13.97
52-Week Range	12.58 - 15.08
Beta	undefined

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Reves...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 5, 2010

Employees 49,281

Stock Exchange NYSE

Ticker Symbol TAK

Website https://www.takeda.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for TAK stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 weeks ago

+2.93%

Takeda Pharmaceutical shares are trading higher af... Unlock content with Pro Subscription

6 months ago

+3.76%

Takeda shares are trading higher after the European Commission approved Adzynma for ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura.

News

1 day ago · zacks.com

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).

4 days ago · zacks.com

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 weeks ago · seekingalpha.com

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, r...

2 weeks ago · seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - Pr...

2 weeks ago · businesswire.com

Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge

BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architect...

2 weeks ago · businesswire.com

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta...

2 weeks ago · reuters.com

Japan's Takeda says Q3 profit slid 38%, trailing analyst estimates

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.

2 weeks ago · businesswire.com

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advanceme...

3 weeks ago · reuters.com

Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

4 weeks ago · reuters.com

Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO

China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.

Load More News